• Publications
  • Influence
Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts
TLDR
A subset of 64 genes was found to give an optimal separation of patients with good and poor outcomes, and the signature associated with prognosis and impact of adjuvant therapies was identified. Expand
Novel patterns of genome rearrangement and their association with survival in breast cancer.
TLDR
Analysis of a selected subset of clinical material suggests that a simple genomic calculation, based on the number and proximity of genomic alterations, correlates with life-table estimates of the probability of overall survival in patients with primary breast cancer. Expand
ADJUVANT TAMOXIFEN IN EARLY BREAST CANCER: OCCURRENCE OF NEW PRIMARY CANCERS
TLDR
The frequency of new primary cancers was studied in 1846 postmenopausal patients included in a randomised trial of tamoxifen as an adjunct to primary surgery for early breast cancer and the increase in endometrial cancers was most pronounced in those treated for over 2 years. Expand
Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients
TLDR
The present study suggests that genotype of metabolic enzymes might be useful as a guide for adjuvant endocrine treatment of postmenopausal breast cancer patients, however, results are in contradiction to prior hypotheses and the present sample size is relatively small. Expand
PIK3CA Mutations and PTEN Loss Correlate with Similar Prognostic Factors and Are Not Mutually Exclusive in Breast Cancer
TLDR
PIK3CA mutations and PTEN loss were not mutually exclusive events and associated with similar prognostic factors, and patients with high S-phase fraction had longer recurrence-free survival if they carried mutations in the Pik3CA gene and/or had lost PTEN. Expand
Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression.
TLDR
Investigating whether hormonal receptors and human epidermal growth factor receptor 2 (HER2) change throughout tumor progression, because this may alter patient management, found marker investigations at relapse may potentially improve patient management and survival. Expand
Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer.
TLDR
The results show that TNBC have higher i.t. VEGF levels compared with non-TNBC, and therapy directed towards angiogenesis may be an alternative way to improve outcome in this poor prognosis group. Expand
Akt kinases in breast cancer and the results of adjuvant therapy
TLDR
Activation of the Akt pathway is correlated with erbB2 overexpression in breast cancer and the results suggest that Akt may predict the local control benefit from radiotherapy. Expand
Transvaginal sonography, saline contrast sonohysterography and hysteroscopy for the investigation of women with postmenopausal bleeding and endometrium > 5 mm
To determine the ability of transvaginal ultrasound, with or without saline infusion, to detect focally growing lesions in the uterine cavity in women with postmenopausal bleeding and endometrium > 5Expand
Immunohistochemistry and biochemistry in detection of androgen, progesterone, and estrogen receptors in benign and malignant human prostatic tissue
The relative distribution of androgen (AR), progesterone (PR), and estrogen receptors (ER) was localized and estimated in human prostate tissue by immunohistochemistry in five normal tissue samples,Expand
...
1
2
3
4
5
...